TaiRx's anti-cancer drug CVM-1118 has delivered impressive clinical data at three major oncology conferences: the American Society of Clinical Oncology (ASCO) in the U.S., ASCO Summit in Japan, and the upcoming European Society for Medical Oncology (ESMO) conference next month. Chairman Andrew Lin announced that TaiRx will actively pursue international collaborations and technology transfer agreements in the next three to six months, which will be critical to the company's plans. If successful, an IPO is planned for next year.
CVM-1118, in combination with an immune checkpoint inhibitor, is undergoing a Phase II clinical trial for advanced liver cancer. The first phase of this trial was presented last week at the ASCO Breakthrough Summit, held in Yokohama, Japan. Additionally, the drug is in a Phase II trial for neuroendocrine tumors, with results scheduled for an oral presentation at the ESMO conference next month.
Du-Shieng Chien, General Manager of TaiRx, emphasized that TaiRx is the only Taiwanese company selected for an oral presentation at ESMO. TaiRx has invited more than four key opinion leaders (KOLs) from Europe and the U.S., who are members of the ESMO Steering Committee responsible for establishing neuroendocrine tumor treatment guidelines, as well as principal investigators (PIs) from teaching hospitals in Taiwan. Their involvement is expected to draw significant international attention to the development of CVM-1118 and increase opportunities for technology transfer or collaborative development with global pharmaceutical companies.
TaiRx has been actively pushing forward with new drug development. Last week at the ASCO Breakthrough Summit in Yokohama, the company presented the results of the Phase II clinical trial of CVM-1118 combined with an immune checkpoint inhibitor for advanced liver cancer. The trial follows a two-phase design, with the first phase aiming to achieve complete response (CR) or partial response (PR) with tumor shrinkage of over 30% in more than five patients.
The trial has already shown that seven patients have met these criteria, and the combination therapy has demonstrated good tolerability without the severe side effects seen in the current standard first-line treatment combination of Tecentriq (atezolizumab) and Avastin (bevacizumab), such as gastrointestinal bleeding and hypertension. This success paves the way for further development and the potential to challenge existing first-line therapies.
Andrew Lin highlighted that this year, TaiRx has been actively presenting research results at various international conferences, including ASCO in Chicago, one-on-one partnering meetings at the US BIO conference in San Diego, discussions with global pharmaceutical companies at BIO Asia in Taiwan, and presentations at the ASCO Summit in Japan. The company is also preparing for an oral presentation at the ESMO conference in Spain and meetings with KOLs from around the world. Through these activities and the publication of research papers, TaiRx aims to connect with major clinical research institutions and international pharmaceutical companies in Europe, the U.S., and Asia, with the goal of accelerating the product's path to market through collaborative efforts.
Resource (mandarin): 台睿CVM-1118新藥三大國際場露臉 林群：將啟動授權、國際合作
